This week's View takes a deep dive into use of a new class of glucose-lowering drugs that has a marked impact on cardiovascular events. Sodium-glucose co-transporter 2 inhibitors compose a class of prescription medicines that is approved by the Food and Drug Administration to lower blood sugar in adults with type 2 diabetes and has also been found to lower cardiovascular risk. Additionally, the ACC first presented information about blood pressure lowering from SPRINT (Systolic Blood Pressure Intervention Trial) when it was first presented at the American Heart Association meeting in 2015. A recently published article in Circulation presents a post-hoc analysis from SPRINT and reviews the effect of intensive blood pressure lowering on the risk of left ventricular hypertrophy. In combination with this article, we will tell you about the timeline for the release of the new hypertension guidelines from ACC, which will answer a lot of questions about blood pressure control.

Subscribe on iTunes | Subscribe on Google Play

Keywords: Metabolic Syndrome, Primary Prevention, Secondary Prevention, Blood Pressure, Hypertension, Diabetes Mellitus, EaglesEyeView

< Back to Listings